SSY Group (HKG:2005) has received approval for the production and registration of Voriconazole for Oral Suspension from China's National Medical Products Administration, according to a Friday bourse filing.
Classified as a type 4 chemical drug, the product has also passed the consistency evaluation.
Voriconazole is indicated to treat various fungal infections, such as invasive aspergillosis, candidemia, and infections caused by Scedosporium and Fusarium.
Additionally, it is prescribed for preventing invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。